Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30155% above fair value
$3.38−0.23 (-6.24%)
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
Aclaris Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Aclaris Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.34M, up 66.6% year over year. For fiscal 2025 it was $52.65M, up 56.7% from the year before. Over ten years it grew 13.1% a year on average. The highest annual figure on record is $98.38M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.65M | +56.7% |
| FY2024 | Dec 31, 2024 | $33.59M | -65.9% |
| FY2023 | Dec 31, 2023 | $98.38M | +26.4% |
| FY2022 | Dec 31, 2022 | $77.81M | +77.6% |
| FY2021 | Dec 31, 2021 | $43.81M | +49.3% |
| FY2020 | Dec 31, 2020 | $29.34M | -54.3% |
| FY2019 | Dec 31, 2019 | $64.17M | +5.5% |
| FY2018 | Dec 31, 2018 | $60.84M | +69.9% |
| FY2017 | Dec 31, 2017 | $35.80M | +7.0% |
| FY2016 | Dec 31, 2016 | $33.48M | +118.2% |
| FY2015 | Dec 31, 2015 | $15.34M | +135.7% |
| FY2014 | Dec 31, 2014 | $6.51M | +86.6% |
| FY2013 | Dec 31, 2013 | $3.49M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.07M | +57.8% |
| Q1 FY2026 | Mar 31, 2026 | $15.66M | +35.2% |
| Q4 FY2025 | Dec 31, 2025 | $16.58M | +83.7% |
| Q3 FY2025 | Sep 30, 2025 | $13.03M | +118.7% |
| Q2 FY2025 | Jun 30, 2025 | $11.45M | +30.7% |
| Q1 FY2025 | Mar 31, 2025 | $11.58M | +17.7% |
| Q4 FY2024 | Dec 31, 2024 | $9.03M | -66.1% |
| Q3 FY2024 | Sep 30, 2024 | $5.96M | -75.1% |
| Q2 FY2024 | Jun 30, 2024 | $8.76M | -65.3% |
| Q1 FY2024 | Mar 31, 2024 | $9.85M | -56.4% |
| Q4 FY2023 | Dec 31, 2023 | $26.65M | +26.5% |
| Q3 FY2023 | Sep 30, 2023 | $23.88M | +0.9% |
| Q2 FY2023 | Jun 30, 2023 | $25.28M | +34.6% |
| Q1 FY2023 | Mar 31, 2023 | $22.59M | +57.9% |
| Q4 FY2022 | Dec 31, 2022 | $21.07M | +49.4% |
| Q3 FY2022 | Sep 30, 2022 | $23.66M | +69.3% |
| Q2 FY2022 | Jun 30, 2022 | $18.78M | +137.8% |
| Q1 FY2022 | Mar 31, 2022 | $14.31M | +82.5% |
| Q4 FY2021 | Dec 31, 2021 | $14.10M | +57.5% |
| Q3 FY2021 | Sep 30, 2021 | $13.98M | +124.0% |
| Q2 FY2021 | Jun 30, 2021 | $7.90M | +22.1% |
| Q1 FY2021 | Mar 31, 2021 | $7.84M | +2.1% |
| Q4 FY2020 | Dec 31, 2020 | $8.96M | -17.3% |
| Q3 FY2020 | Sep 30, 2020 | $6.24M | -61.4% |
| Q2 FY2020 | Jun 30, 2020 | $6.47M | -63.1% |
| Q1 FY2020 | Mar 31, 2020 | $7.68M | -60.9% |
| Q4 FY2019 | Dec 31, 2019 | $10.83M | -44.1% |
| Q3 FY2019 | Sep 30, 2019 | $16.18M | +6.5% |
| Q2 FY2019 | Jun 30, 2019 | $17.52M | +25.3% |
| Q1 FY2019 | Mar 31, 2019 | $19.64M | +44.4% |
| Q4 FY2018 | Dec 31, 2018 | $19.36M | +110.4% |
| Q3 FY2018 | Sep 30, 2018 | $15.19M | +39.8% |
| Q2 FY2018 | Jun 30, 2018 | $13.98M | +75.6% |
| Q1 FY2018 | Mar 31, 2018 | $13.61M | +75.1% |
| Q4 FY2017 | Dec 31, 2017 | $9.20M | +32.6% |
| Q3 FY2017 | Sep 30, 2017 | $10.86M | +51.7% |
| Q2 FY2017 | Jun 30, 2017 | $7.97M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.94M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.16M | – |
See a number that looks wrong?